Impact of CD4+ T-cell count on sustained virologic response to direct-acting antivirals in hepatitis C virus monoinfected cancer patients: a prospective observational study.

Georgios Angelidakis, Haley Pritchard, Marcel Yibirin, Ying Jiang, Khalis Mustafayev, Harrys A Torres

Journal: Diagnostic microbiology and infectious disease 2022;103(3):115719

PMID: 35605562

Full Text on Elsevier Science View on PubMed

Abstract

Limited data are available on the use of CD4+ T-cell count and percentage to predict response to direct-acting antiviral (DAA) treatment outside the hepatitis C virus (HCV)-HIV coinfected population. We sought to determine the impact of CD4+ T-cell count and percentage on response to DAAs in cancer patients with HCV monoinfection. Patients treated with DAAs were enrolled in a prospective observational study. CD4+ T-cell count and percentage was measured at baseline, end of treatment (EOT), and 12 weeks after the EOT (SVR12). A total of 174 patients were enrolled. Most patients (155/174, 89%) achieved an SVR12. A multivariate logistic regression model found that patients with hepatocellular carcinoma, HCV-3 and previous DAA treatment were more likely to develop treatment failure. Neither univariate analysis nor multivariate logistic regression analysis did show any association between CD4+ T-cell count or percentage and SVR12. CD4 T-cell count or percentage does not appear to impact SVR rates in cancer patients with HCV monoinfection receiving DAAs.

Address: Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX, USA.; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: [email protected].

DOI: 10.1016/j.diagmicrobio.2022.115719

Link outs

Free resources

Medical:

https://medlineplus.gov/hepatitisc.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-CD4-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Antiviral Agents, CD4-Positive T-Lymphocytes, HIV Infections, Hepacivirus, Hepatitis C, Hepatitis C, Chronic, Humans, Neoplasms, Sustained Virologic Response, Treatment Outcome